New combo aims to keep leukemia away after remission
NCT ID NCT07537257
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding venetoclax to standard chemotherapy (cytarabine) can help adults with acute myeloid leukemia (AML) stay in remission longer. About 232 participants who are already in remission will receive either the combination or chemo alone. The main goal is to see if the combo leads to a higher rate of undetectable leukemia cells (MRD-negative), which is linked to better outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venetoclax and cytarabine
- What this could lead to
- If successful, this combination could become a new standard consolidation therapy, helping more AML patients achieve deep remission and potentially reducing relapse risk.
- What could go wrong
- This is a mid-stage trial with 232 participants, so results are not yet conclusive. Adding venetoclax may increase side effects like low blood counts or infections, and the benefit over standard care is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Hematology, Guangdong Second Provincial General Hospital
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can umbilical cord blood keep leukemia at bay in older patients?
- Can a new drug combo reset the immune system to beat relapsed leukemia?
- New chemo cocktail aims to boost stem cell transplant success in leukemia
- New blood test may predict cancer relapse after transplant
- Fitness check may guide better leukemia care for seniors
- New trial aims to match AML patients with best drug combo